Ceres Nanosciences
Manassas
About Ceres Nanosciences
Ceres Nanosciences Inc. (“Ceres”) is a privately held life sciences company engaged in the research, development, and commercialization of innovative sample preparation products, based on its proprietary Nanotrap® technology, which captures, enriches and preserves analytes/biomarkers. Early detection of biomarkers, in particular those of low abundance, is key to the diagnosis and treatment of diseases such as cancer, cardiac, and infectious diseases, resulting in improved patient benefit and reduced health care costs. Ceres has a broad product pipeline of advanced sample collection technologies and diagnostics, funded through federal agency grants and industry collaboration funding. Ceres’ lead product in development is a direct antigen test for the diagnosis of Lyme disease, which will be available commercially in 2015.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $24.5M
- Last round: Series Unknown (Sep 2022)
- Website: ceresnano.com
- Phone: (800) 615-0418
Industries & Categories
Biotechnology, Product Research, Web Development
Social Profiles
Canonical: https://fsome.com/organization/ceres-nanosciences-145948 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.